Fig. 6.

A: dose effects of HET0016 treatment on subcutaneous MC38 tumors in C57B6 mice. MC38 colon tumor-bearing mice (1.4 × 10⁶ cells/mouse, injected subcutaneously) were divided into vehicle, HET0016 (5 mg·kg⁻¹·day⁻¹ ip), or HET0016 (10 mg·kg⁻¹·day⁻¹ ip) treatment groups. After 9 or 18 days postimplantation, tumor volumes were determined using a sliding caliper. B: effects of rofecoxib + HET0016 on tumor growth in MC38 tumor mice. MC38 tumor mice were divided into vehicle, rofecoxib (50 mg/l), HET0016 (5 mg·kg⁻¹·day⁻¹ ip), or rofecoxib + HET0016 treatment groups. After 9 and 18 days postimplantation, tumor volumes were determined. Values are means ± SE; n = 6. *P < 0.05, **P < 0.01 vs. vehicle. #P < 0.05 vs. other groups.